Keyword: iTeos Therapeutics
Allergan taps Celgene vet Bob Hugin for M&A guidance; Imara gains a Pfizer rare disease exec as CMO; and iTeos brings on Sanofi cancer VP as CMO.
Belgian immunotherapy developer iTeos Therapeutics has snagged Sanofi’s cancer drug development leader, Joanne Lager, M.D., to be its new CMO.
Surface Oncology’s Detlev Biniszkiewicz and Scott Chappel jumped to MPM Capital as executive partners to help identify oncology startup ventures.
The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year.
Pfizer dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future.